BFM
CYTO

Boothbay Fund Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Boothbay Fund Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-77
Closed -$34K – 2806
2022
Q1 		$34K Hold
77
– – ﹤0.01% 2217
2021
Q4 		$56K Sell
77
-24
-24% -$16.1K ﹤0.01% 1770
2021
Q3 		$81K Buy
+101
New +$114K ﹤0.01% 1821
2021
Q2 		– Sell
-129
Closed -$180K – 2205
2021
Q1 		$180K Buy
+129
New +$173K 0.01% 1386

Other funds holding CYTO

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Boothbay Fund Management's CYTO Position: Q2 2022 in Review

Boothbay Fund Management sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2022, closing a stake of 77 shares — an estimated $34K sold.

Boothbay Fund Management first reported a position in CYTO in Q1 2021 and held it in 4 quarters. The position peaked at $180K in Q1 2021. 12 funds tracked by Wall St. Rank hold CYTO as of Q2 2022.

  • Boothbay Fund Management reported no remaining Altamira Therapeutics Ltd position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 77 Altamira Therapeutics Ltd shares in Q2 2022, an estimated $34K.
  • Boothbay Fund Management first reported a position in Altamira Therapeutics Ltd in Q1 2021 and held it in 4 quarters.
  • Boothbay Fund Management's Altamira Therapeutics Ltd position peaked at $180K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.